The brand name for lisdexamfetamine dimesylate is Vyvanse [1][2].
What is Vyvanse used to treat?
Vyvanse is prescribed to treat Attention Deficit Hyperactivity Disorder (ADHD) in both children and adults [1][3]. It is also approved for the treatment of moderate to severe binge eating disorder in adults [1][4].
How does lisdexamfetamine dimesylate work?
Lisdexamfetamine dimesylate is a prodrug, meaning it is converted into its active form, dextroamphetamine, in the body [2][5]. This conversion process is thought to be primarily enzymatic in the blood. Once converted to dextroamphetamine, it acts as a central nervous system stimulant [5].
When does the patent for Vyvanse expire?
The patent landscape for Vyvanse is complex, with multiple patents covering the drug and its uses [6]. For example, U.S. Patent No. 7,132,099, which covers lisdexamfetamine, is listed as expiring in 2026 [7]. However, patent expiration dates can be affected by various factors, including patent challenges and extensions, which may influence when generic versions can enter the market [6]. Information on specific patent expirations and potential challenges can be found on sites like DrugPatentWatch.com [6].
Can generic versions of Vyvanse be available?
The availability of generic versions of Vyvanse depends on patent expirations and any associated legal proceedings [6]. Typically, once relevant patents expire and any market exclusivities have ended, generic manufacturers can seek FDA approval to market their versions of the drug.
What are the side effects of Vyvanse?
Common side effects of Vyvanse include decreased appetite, dry mouth, difficulty sleeping, and weight loss [1]. More serious side effects can include cardiovascular problems, psychiatric symptoms, and problems with blood circulation [3]. Patients should discuss any potential side effects with their healthcare provider [3].